1887

Abstract

Irritable bowel syndrome (IBS) is a common, typically chronic and sometimes disabling gastrointestinal condition of uncertain aetiology. Recently, a variety of links to gastrointestinal infections have been described including the onset of IBS following exposure to enteric pathogens and an apparent predisposition to gastrointestinal infection. The prevalence of in a population of IBS outpatients ( = 87) in the absence of established risk factors for the acquisition of infection was examined. Overall, 5.7 % of patients ( = 5) carried culturable and 4.6 % ( = 4) of isolates were toxigenic, belonging to toxinotype group 0, compared with 1.1 % ( = 1) for the healthy control group ( = 88). These isolates were members of toxigenic PCR ribotype groups 005 and 050 (IBS group) and 062 (control group) and were identified further as three individual strains by PFGE. Although no significant difference was observed between IBS patients and healthy volunteers, these findings support the concept that a subpopulation of IBS patients may be susceptible to gastrointestinal infection.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.040568-0
2012-09-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jmm/61/9/1290.html?itemId=/content/journal/jmm/10.1099/jmm.0.040568-0&mimeType=html&fmt=ahah

References

  1. Barbut F., Mastrantonio P., Delmée M., Brazier J., Kuijper E., Poxton I. European Study Group on Clostridium difficile (ESGCD) 2007; Prospective study of Clostridium difficile infections in Europe with phenotypic and genotypic characterisation of the isolates. Clin Microbiol Infect 13:1048–1057[PubMed] [CrossRef]
    [Google Scholar]
  2. Borody T. J., George L., Andrews P., Brandl S., Noonan S., Cole P., Hyland L., Morgan A., Maysey J., Moore-Jones D. 1989; Bowel-flora alteration: a potential cure for inflammatory bowel disease and irritable bowel syndrome?. Med J Aust 150:604[PubMed]
    [Google Scholar]
  3. Braun V., Hundsberger T., Leukel P., Sauerborn M., von Eichel-Streiber C. 1996; Definition of the single integration site of the pathogenicity locus in Clostridium difficile . Gene 181:29–38 [View Article][PubMed]
    [Google Scholar]
  4. Carter G. P., Lyras D., Allen D. L., Mackin K. E., Howarth P. M., O’Connor J. R., Rood J. I. 2007; Binary toxin production in Clostridium difficile is regulated by CdtR, a LytTR family response regulator. J Bacteriol 189:7290–7301 [View Article][PubMed]
    [Google Scholar]
  5. Cartwright C. P., Stock F., Beekmann S. E., Williams E. C., Gill V. J. 1995; PCR amplification of rRNA intergenic spacer regions as a method for epidemiologic typing of Clostridium difficile . J Clin Microbiol 33:184–187[PubMed]
    [Google Scholar]
  6. Clayton E. M., Rea M. C., Shanahan F., Quigley E. M., Kiely B., Hill C., Ross R. P. 2009; The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol 104:1162–1169 [View Article][PubMed]
    [Google Scholar]
  7. Curry S. R., Marsh J. W., Muto C. A., O’Leary M. M., Pasculle A. W., Harrison L. H. 2007; tcdC genotypes associated with severe TcdC truncation in an epidemic clone and other strains of Clostridium difficile . J Clin Microbiol 45:215–221 [View Article][PubMed]
    [Google Scholar]
  8. Drossman D. A., Camilleri M., Mayer E. A., Whitehead W. E. 2002; AGA technical review on irritable bowel syndrome. Gastroenterology 123:2108–2131 [View Article][PubMed]
    [Google Scholar]
  9. Drudy D., Quinn T., O’Mahony R., Kyne L., O’Gaora P., Fanning S. 2006; High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile . J Antimicrob Chemother 58:1264–1267 [View Article][PubMed]
    [Google Scholar]
  10. Geric B., Rupnik M., Gerding D. N., Grabnar M., Johnson S. 2004; Distribution of Clostridium difficile variant toxinotypes and strains with binary toxin genes among clinical isolates in an American hospital. J Med Microbiol 53:887–894 [View Article][PubMed]
    [Google Scholar]
  11. Jamal W. Y., Mokaddas E. M., Verghese T. L., Rotimi V. O. 2002; In vitro activity of 15 antimicrobial agents against clinical isolates of Clostridium difficile in Kuwait. Int J Antimicrob Agents 20:270–274 [View Article][PubMed]
    [Google Scholar]
  12. John R., Brazier J. S. 2005; Antimicrobial susceptibility of polymerase chain reaction ribotypes of Clostridium difficile commonly isolated from symptomatic hospital patients in the UK. J Hosp Infect 61:11–14 [View Article][PubMed]
    [Google Scholar]
  13. Kassinen A., Krogius-Kurikka L., Mäkivuokko H., Rinttilä T., Paulin L., Corander J., Malinen E., Apajalahti J., Palva A. 2007; The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology 133:24–33 [View Article][PubMed]
    [Google Scholar]
  14. Lyerly D. M., Saum K. E., MacDonald D. K., Wilkins T. D. 1985; Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun 47:349–352[PubMed]
    [Google Scholar]
  15. Malinen E., Rinttilä T., Kajander K., Mättö J., Kassinen A., Krogius L., Saarela M., Korpela R., Palva A. 2005; Analysis of the fecal microbiota of irritable bowel syndrome patients and healthy controls with real-time PCR. Am J Gastroenterol 100:373–382 [View Article][PubMed]
    [Google Scholar]
  16. Mättö J., Maunuksela L., Kajander K., Palva A., Korpela R., Kassinen A., Saarela M. 2005; Composition and temporal stability of gastrointestinal microbiota in irritable bowel syndrome – a longitudinal study in IBS and control subjects. FEMS Immunol Med Microbiol 43:213–222 [View Article][PubMed]
    [Google Scholar]
  17. Parkes G. C., Brostoff J., Whelan K., Sanderson J. D. 2008; Gastrointestinal microbiota in irritable bowel syndrome: their role in its pathogenesis and treatment. Am J Gastroenterol 103:1557–1567 [View Article][PubMed]
    [Google Scholar]
  18. Pimentel M., Chow E. J., Lin H. C. 2000; Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 95:3503–3506 [View Article][PubMed]
    [Google Scholar]
  19. Pimentel M., Park S., Mirocha J., Kane S. V., Kong Y. 2006; The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 145:557–563[PubMed] [CrossRef]
    [Google Scholar]
  20. Popoff M. R., Rubin E. J., Gill D. M., Boquet P. 1988; Actin-specific ADP-ribosyltransferase produced by a Clostridium difficile strain. Infect Immun 56:2299–2306[PubMed]
    [Google Scholar]
  21. Quigley E. M. 2006; Changing face of irritable bowel syndrome. World J Gastroenterol 12:1–5[PubMed]
    [Google Scholar]
  22. Quigley E. M. 2007; Bacterial flora in irritable bowel syndrome: role in pathophysiology, implications for management. J Dig Dis 8:2–7 [View Article][PubMed]
    [Google Scholar]
  23. Rupnik M. 2008; Heterogeneity of large clostridial toxins: importance of Clostridium difficile toxinotypes. FEMS Microbiol Rev 32:541–555 [View Article][PubMed]
    [Google Scholar]
  24. Rupnik M., Avesani V., Janc M., von Eichel-Streiber C., Delmée M. 1998; A novel toxinotyping scheme and correlation of toxinotypes with serogroups of Clostridium difficile isolates. J Clin Microbiol 36:2240–2247[PubMed]
    [Google Scholar]
  25. Sharara A. I., Aoun E., Abdul-Baki H., Mounzer R., Sidani S., Elhajj I. 2006; A randomized double-blind placebo-controlled trial of rifaximin in patients with abdominal bloating and flatulence. Am J Gastroenterol 101:326–333 [View Article][PubMed]
    [Google Scholar]
  26. Simpson P. J., Stanton C., Fitzgerald G. F., Ross R. P. 2003; Genomic diversity and relatedness of bifidobacteria isolated from a porcine cecum. J Bacteriol 185:2571–2581 [View Article][PubMed]
    [Google Scholar]
  27. Spigaglia P., Mastrantonio P. 2002; Molecular analysis of the pathogenicity locus and polymorphism in the putative negative regulator of toxin production (TcdC) among Clostridium difficile clinical isolates. J Clin Microbiol 40:3470–3475 [View Article][PubMed]
    [Google Scholar]
  28. Spiller R. C. 2003; Estimating the importance of infection in IBS. Am J Gastroenterol 98:238–241 [View Article][PubMed]
    [Google Scholar]
  29. Spiller R. C. 2007; Role of infection in irritable bowel syndrome. J Gastroenterol 42:Suppl. 1741–47 [View Article][PubMed]
    [Google Scholar]
  30. Stubbs S. L., Brazier J. S., O’Neill G. L., Duerden B. I. 1999; PCR targeted to the 16S–23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 37:461–463[PubMed]
    [Google Scholar]
  31. Stubbs S., Rupnik M., Gibert M., Brazier J., Duerden B., Popoff M. 2000; Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile . FEMS Microbiol Lett 186:307–312 [View Article][PubMed]
    [Google Scholar]
  32. Wilcox M. 2010 Clostridium difficile ribotyping network (CDRN) for England and Northern Ireland (2009/2010)
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.040568-0
Loading
/content/journal/jmm/10.1099/jmm.0.040568-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error